J Korean Neuropsychiatr Assoc.  2022 Aug;61(3):224-236. 10.4306/jknpa.2022.61.3.224.

Korean Medication Algorithm Project for Bipolar Disorder 2022: Children and Adolescents

Affiliations
  • 1Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine, Iksan, Korea
  • 2Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea
  • 3Department of Psychiatry, College of Medicine, Chung-Ang University, Seoul, Korea
  • 4Department of psychiatry, Chosun University Hospital, College of Medicine, Chosun University, Gwangju, Korea
  • 5Department of Psychiatry, Sanggye Paik Hospital, College of Medicine, Inje University, Seoul, Korea
  • 6Department of Psychiatry, Haeundae Paik Hospital, College of Medicine, Inje University, Busan, Korea
  • 7Department of Psychiatry, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang, Korea
  • 8Department of Psychiatry, Keyo Hospital, Uiwang, Korea
  • 9Department of Psychiatry, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, Korea
  • 10Department of Psychiatry, Naju National Hospital, Naju, Korea
  • 11Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea

Abstract


Objectives
The objective of this study was to revise the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) 2022: children and adolescents.
Methods
We performed a survey, using a questionnaire comprising 23 questions according to various situations facing children and adolescents with bipolar disorders. A total of 40 of the 60 experts in child and adolescent psychiatry responded to the survey.
Results
The first-line pharmacotherapeutic strategies for manic and depressive episodes in children with bipolar disorders were a combination of mood stabilizer (MS) and atypical antipsychotics (AAP). The first-line medications selected for these children were aripiprazole (treatment of choice, TOC) and risperidone. The first-line pharmacotherapeutic strategies for manic episodes in adolescents were a combination of MS and an AAP (TOC), monotherapy with MS, and monotherapy with an AAP. Lithium, valproate, aripiprazole, risperidone, and quetiapine were selected as first-line medications for these adolescents. First-line pharmacotherapeutic strategies for depressive episodes in adolescents were a combination of MS and an AAP, monotherapy with MS, and monotherapy with an AAP. The first-line pharmacotherapeutic strategies for the depressive episodes in adolescents at high risk for bipolar disorder were a combination of MS and AAP and monotherapy with an AAP. Lithium, valproate, aripiprazole (TOC), quetiapine, and risperidone were selected as first-line medications for the treatment of depressive episodes in adolescents with bipolar disorder.
Conclusion
It is expected that the present KMAP-BP 2022: children and adolescents will give the direction and be usefully applied by clinicians to treat children and adolescents with bipolar disorders.

Keyword

Bipolar disorder; Children and adolescents; Pharmacotherapy; KMAP-BP 2022
Full Text Links
  • JKNA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr